Silvia Aguilera

@silvia-aps.bsky.social

IMPACT Trial Certolizumab in high-risk pregnancies (APS + LAC): • Complications: ↓ from 80% to 20% • Gestational age: ↑ from 24 to 36.5 weeks • Live births: ↑ from 38% to 93% Huge congratulations to Jane Salmon & team – truly transformative results!

Bild

It was a pleasure to participate in the session "Inclusion of pregnant patients with chronic conditions in research and clinical trials" in #RheumaPreg25 Such an honor to exchange with these wonderful women and incredible experts! 😍

SAF España@afosfolipido.bsky.social · last yr.

📍Estamos en Viena en #RheumaPreg25 Nuestra vicepresidenta trae la voz de pacientes al panel sobre los desafíos en la investigación en embarazo y lactancia con @lauraandreoli.bsky.social, Klara Rosta @rheproat.bsky.social, @karenschreiber.bsky.social Judit Sandor y @nelson-piercy.bsky.social

Day 2 of RheumaPreg 2025 is underway! Today’s sessions focus on clinical research in pregnancy, obstetric APS, neonatal lupus, immunosuppression during pregnancy, and hormonal influences in rheumatic diseases. Stay tuned for more insights and discussion.

Bild